{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005405","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.283468+00:00","generated_at":"2026-05-17T13:24:36.161044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MiNK Therapeutics Q2 2025 net loss $4.2M; extends runway with $13M raise; GvHD grants awarded","bullets":["Cash at Q2 end $1.6M; raised $13M post-quarter; runway extended beyond mid-2026.","Net loss Q2 2025 $4.2M ($1.06/shr) vs $2.7M ($0.73/shr) in Q2 2024.","Durable complete remission in metastatic testicular cancer published; patient disease-free >2 years.","DOD STTR grant and new clinical grant awarded for iNKT cell therapy in GvHD; trial target 2H2025.","Phase 2 gastric cancer trial of agenT-797 expects additional readouts in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005405","json":"https://secwatch.observer/filing/0001171843-25-005405.json","markdown":"https://secwatch.observer/filing/0001171843-25-005405.md","text":"https://secwatch.observer/filing/0001171843-25-005405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184325005405/0001171843-25-005405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184325005405/f8k_081425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:24:36.161044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}